GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Exelixis, Inc. (EXEL) [hlAlert]

Rating:
Buy EXEL
down 41.72 %

Exelixis, Inc. (EXEL) rated Buy with price target $8 by Lazard Capital

Posted on: Monday,  Dec 15, 2008  9:25 AM ET by Lazard Capital

Lazard Capital rated Buy Exelixis, Inc. (NASDAQ: EXEL) on 12/15/2008. Previously Lazard Capital rated Buy Exelixis, Inc. (NASDAQ: EXEL) on 09/14/2007.,
when the stock price was $10.45. Since then, Exelixis, Inc. has lost 41.72% as of 08/27/2015's recent price of $6.09.
If you would have followed the previous Lazard Capital's recommendation on EXEL, you would have lost 41.72% of your investment in 2904 days.

Exelixis, Inc. (Exelixis) is developing therapies for cancer and other serious diseases. Through its drug discovery and development activities, the Company is building a portfolio of novel compounds. Exelixis has a pipeline of compounds in various stages of development that will potentially treat cancer, renal disease and various metabolic and cardiovascular disorders. Its most advanced pharmaceutical programs focus on drug discovery and development of small molecule drugs for cancer. The Company has nine compounds in clinical development: XL184, XL147, XL765, XL518, XL228, XL019, XL139, XL413 and XL888. Exelixis also has out-licensed to third parties for further development and commercialization of five compounds in preclinical and clinical development: XL880, XL281, XL652, XL550 and FXR Program. The Company has established commercial collaborations with several pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Genentech, Inc. and GlaxoSmithKline.

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Our goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Our industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/15/2008 9:25 AM Buy
None
5.30 8.00
as of 12/24/2008
1 Week down  -8.68 %
1 Month up  6.46 %
3 Months up  11.01 %
1 YTD down  -1.59 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/24/2008 12:25 PM Buy
None
2.86 7.00
8/6/2008 9:25 AM Buy
None
6.18 10.00
9/14/2007 9:25 AM Buy
None
10.45 14.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy